Combination Therapy Reversing Beta-Cell Loss in Type 1 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 1 diabetes (T1D) are unable to effectively restore lost β-cell mass and function, and existing immunomodulatory therapies only delay disease progression without reversing β-cell loss.
Innovation Solution
A method involving the administration of a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor, a glucagon-like peptide-1 receptor (GLP1R) agonist, and an immunomodulatory monoclonal antibody, such as an anti-CD3 antibody, to reverse loss of β-cell mass and function in subjects with T1D.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If immunomodulatory therapies are used to delay disease progression, then β-cell function is preserved temporarily, but lost β-cell mass cannot be restored
Solution Approach 1:
The patent combines three distinct therapeutic mechanisms into a single treatment regimen: immunomodulation (anti-CD3 antibody) to control autoimmune attack, DYRK1A inhibition (harmine) to promote β-cell replication, and GLP1R agonism (exendin-4) to enhance β-cell survival and function. This combination enables both preservation of remaining β-cells and regeneration of lost β-cell mass, resolving the contradiction between temporary function preservation and permanent mass restoration
2Object-affected harmful factors
If high doses of anti-CD3 antibody are used to modify autoreactive T-cells, then β-cell destruction is reduced, but lymphoproliferative disorders may occur
Solution Approach 1:
The patent changes the dosage parameter of anti-CD3 antibody from high dose to low dose (0.3-3 mg/kg), which is sufficient to modify autoreactive T-cells and reduce β-cell destruction without causing lymphoproliferative disorders. This dose optimization, combined with the synergistic effects of DYRK1A inhibition and GLP1R agonism, achieves therapeutic benefit while minimizing adverse effects
3Quantity of substance
If pancreas or islet transplantation is performed to replace lost β-cells, then insulin production is restored, but the approach is not scalable or cost-effective
Solution Approach 1:
The patent enables the patient's own β-cells to regenerate and repopulate the pancreas through pharmacological stimulation of β-cell replication (DYRK1A inhibition) and survival (GLP1R agonism). This endogenous regeneration approach eliminates the need for complex transplantation procedures, donor organ matching, and lifelong immunosuppression, making the therapy scalable and cost-effective while restoring β-cell mass
Data Source
AI summary
Disclosed herein are methods of treating a subject for a condition associated with insufficient insulin secretion by administering to a subject in need of treatment for a condition associated with an insufficient level of insulin secretion a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor, a glucagon-like peptide-1 receptor (GLP1R) agonist, and an immunomodulatory monoclonal antibody and/or an immunosuppressive agent (e.g., anti-CD3 antibody), where said administering is carried out under conditions effective to reverse loss of β-cell mass and function in the subject to treat the subject for the condition associate with insufficient insulin secretion. Also disclosed is a composition and a method of increasing β-cell mass and function in a population of pancreatic beta cells.